Search

Your search keyword '"Czubkowski, Piotr"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Czubkowski, Piotr" Remove constraint Author: "Czubkowski, Piotr" Publisher elsevier bv Remove constraint Publisher: elsevier bv
28 results on '"Czubkowski, Piotr"'

Search Results

1. SAT-021 Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival in an international multicentre cohort

2. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

3. Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC

4. Efficacy and safety outcomes with odevixibat treatment: Pooled data from the phase 3 ASSERT and ASSERT-EXT studies in patients with Alagille syndrome

5. Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database

6. Serum bile acids are associated with native liver survival in patients with Alagille syndrome: results from the GALA study group

7. Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): data from the MARCH-ON study

8. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis

9. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency

10. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency

11. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis

12. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial

13. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation

14. Analysis of quality of life, hepatic biochemical markers, and sleep in patients with progressive familial intrahepatic cholestasis who had a pruritus response with odevixibat treatment

15. Efficacy and safety of odevixibat over 72 weeks of treatment in patients with progressive familial intrahepatic cholestasis

16. EP1228: DISEASE BURDEN AND NATURAL HISTORY OF PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: BASELINE CLINICAL CHARACTERISTICS AMONG ODEVIXIBAT-TREATED PATIENTS IN THE PHASE 3 PEDFIC STUDIES

17. EP1229: RELATIONSHIPS BETWEEN DECREASES IN SERUM BILE ACIDS, PRURITUS, AND SLEEP DISTURBANCE SCORES WITH UP TO 72 WEEKS OF ODEVIXIBAT TREATMENT IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS

18. EP1232: ODEVIXIBAT EFFECTS ON CHOLESTASIS-RELATED PARAMETERS: ANALYSIS OF POOLED DATA FROM THE PEDFIC 1 AND PEDFIC 2 STUDIES IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS

22. Clinical features and natural history of 1154 Alagille syndrome patients: results from the international multicenter GALA study group

23. The phenotype of compound heterozygous BSEP deficiency patients is determined by the combined residual function of the two ABCB11 mutations: results from the NAPPED consortium

24. PS-195-Predicting long-term outcome after surgical biliary diversion in Bsep-deficiency patients: Results from the NAPPED consortium

25. PS-195-Predicting long-term outcome after surgical biliary diversion in Bsep-deficiency patients: Results from the NAPPED consortium

28. Differences in presentation and progression between severe FIC1 and BSEP deficiencies

Catalog

Books, media, physical & digital resources